Toronto Dominion Bank raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 46.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 397,213 shares of the biopharmaceutical company’s stock after buying an additional 125,225 shares during the period. Toronto Dominion Bank’s holdings in Gilead Sciences were worth $26,978,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $997,048,000. Parnassus Investments CA raised its stake in Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Numeric Investors LLC raised its stake in Gilead Sciences by 173.5% in the fourth quarter. Numeric Investors LLC now owns 2,820,505 shares of the biopharmaceutical company’s stock valued at $201,976,000 after buying an additional 1,789,101 shares during the last quarter. Finally, Swiss National Bank raised its stake in Gilead Sciences by 26.9% in the first quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock valued at $317,059,000 after buying an additional 989,400 shares during the last quarter. 74.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (GILD) traded down 0.32% during trading on Friday, reaching $72.11. 6,052,601 shares of the company traded hands. The company’s 50-day moving average price is $72.61 and its 200-day moving average price is $68.83. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10. The company has a market capitalization of $94.17 billion, a P/E ratio of 7.83 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue was down 8.2% on a year-over-year basis. During the same period last year, the company earned $3.08 earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.88%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/toronto-dominion-bank-has-26-98-million-position-in-gilead-sciences-inc-nasdaqgild-updated-updated.html.
A number of analysts recently weighed in on the stock. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 21st. Piper Jaffray Companies reissued a “buy” rating on shares of Gilead Sciences in a report on Friday, April 21st. Barclays PLC reaffirmed an “overweight” rating and issued a $85.00 price objective (down from $90.00) on shares of Gilead Sciences in a research note on Sunday, April 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research note on Monday, April 24th. Finally, Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price target on the stock. in a research report on Tuesday, April 25th. Twelve analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $80.31.
In other news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now directly owns 106,113 shares in the company, valued at $8,051,854.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,666 shares of company stock valued at $15,223,184. Corporate insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.